An interventional study of Pulmonary artery denervation and Sham procedure in Pulmonary Arterial Hypertension, sponsored by SoniVie Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-01.
Sponsored by SoniVie Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Theis is a prospective, multicenter, blinded, randomized sham controlled pivotal clinical trial with a crossover at 6M, to assess the safety and effectiveness of pulmonary artery denervation with the TIVUS™ System in subjects with PAH. The study will assess improved and/or maintained exercise tolerance in patients with PAH through the analysis of exercise tolerance, hemodynamic changes, clinical worsening and the quality of life who got treated by the TIVUS system.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
This study's planned enrollment of 205 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Browse Pulmonary Arterial Hypertension studies →SoniVie Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject with known pulmonary arterial hypertension (PAH), which has been diagnosed as idiopathic PAH, connective tissue disease PAH, anorexigen induced, familial PAH or corrected congenital heart defects more than 1 year prior to enrollment, confirmed by right heart catheterization performed prior to screening and showing all of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pulmonary artery denervation with the TIVUS™ System will be performed immediately after the right heart catheterization and pulmonary artery angiography.
Device: Pulmonary artery denervation
A sham treatment of pulmonary artery denervation with the TIVUS™ System will be performed immediately after the right heart catheterization pulmonary artery angiography. The sham procedure will be identical to the denervation procedure, with the only exception that the procedure will use a sham setting on the control console.
Device: Sham procedure
The TIVUS system will be used for pulmonary artery denervation using non focused ultrasound
A sham procedure would be performed using the TIVUS system without delivering the non focused ultrasound
6 minute walking distance (6MWD)
Statistical difference in 6MWD between the treated group and the sham control group
Time frame: 6 months
The rate of procedure and treatment related SAEs reported
Time frame: 12 months
Statistical difference between the treated group and the sham control group in exercise tolerance as measured using the change in activity parameters using the Actigraph Centrepoint watch
Time frame: 6 months
Difference between time to clinical worsening event between the treated group and the sham control group
Time frame: 6 months
Difference between the number of clinical worsening events between the treated group and the sham control group
The definition of clinical worsening events includes: all cause death, hospitalization for worsening PAH, lung/heart transplant, arterial septostomy, initiation of parenteral prostanoid therapy, change in dose and/or number of PAH specific medication. Each event will be counted as a single event and per each patient the total number of events will be recorded
Time frame: 6 months
Difference between the treated group and the sham control group in resting mean right atrial pressure (mRAP)
Time frame: 6 months
Difference between the treated group and the sham control group in resting mean pulmonary artery pressure (mPAP)
Time frame: 6 months
Difference between the treated group and the sham control group in resting pulmonary vascular resistance (PVR)
Time frame: 6 months
Difference between the treated group and the sham control group in resting cardiac index (CI)
Time frame: 6 months
Difference between the treated group and the sham control group in Quality of Life (QOL) score using the SF36 questionnaire
The SF36 is a 0-100 score, the lower the score is the lower the quality of life is, so that zero is equivalent to maximum disability and a score of 100 is equivalent to no disability at all
Time frame: 6 months
Difference between the treated group and the sham control group of NT-pro-BNP levels
Time frame: 6 months
Difference between the treated group and the sham control group in patients' clinical pulmonary arterial hypertension condition defined by worsening of World Health Organization (WHO) functional class
PAH patient's WHO functional class is a scale of 1 to 4 based on the symptoms patient experience when doing everyday activities, were Functional Class 1 and 2 are associated with limited effect on patient activity and lower risk status, and Functional Class 3 and 4 are associated with limited activity and higher risk status
Time frame: 6 months
Percent of patients who improve or maintain their exercise tolerance (as measured by 6MWD and actigraphy)
Time frame: 6 months
Clinical change of pulmonary arterial hypertension condition defined by escalation of PAH specific drug therapy
Change in the dose of medication
Time frame: 6, 12, 24, 36 month
Clinical change of pulmonary arterial hypertension condition defined by escalation of PAH specific drug therapy
Change in the number of PAH specific medication
Time frame: 6, 12, 24, 36 month
Clinical change of pulmonary arterial hypertension condition defined by escalation of concomitant drug therapy
Change in the number of concomitant medication
Time frame: 6, 12, 24, 36 month
Clinical change of pulmonary arterial hypertension condition defined by escalation of concomitant drug therapy
Change in dose of a medication
Time frame: 6, 12, 24, 36 month
Clinical change of pulmonary arterial hypertension condition defined by change from baseline of ECG parameters demonstrating initiation or worsening of heart block
Heart block is defined as long PR interval, wide or narrow QRS complex and/or QRS complex in various leads are oriented rightward and anteriorly. Heart block will be noted as either present or not present. Any change from baseline will be noted.
Time frame: 6, 12, 24, 36 month
Clinical change of pulmonary arterial hypertension condition defined by change from baseline of ECG parameters indicating initiation or worsening of arrhythmia
Arrhythmia is defined when the P-P interval and/or R-R interval has differences of more than 10% and/or there are no visible P waves and/or irregularly irregular QRS complex is present. Arrhythmia will be noted as either present or not present. Any change from baseline will be noted.
Time frame: 6, 12, 24, 36 month
Clinical change of pulmonary arterial hypertension condition defined by change from baseline of ECG parameters indicating initiation or worsening of right ventricular hypertrophy (RVH)
Right ventricular hypertrophy is when the following are present: right axis deviation \> 90 degrees, tall R-waves in RV leads; deep S-waves in LV leads, slight increase in QRS duration and ST-T changes directed opposite to QRS direction (i.e., wide QRS/T angle). Right ventricular hypertrophy will be noted as either present or not present. Any change from baseline will be noted.
Time frame: 6, 12, 24, 36 month
Clinical change of pulmonary arterial hypertension condition defined by change from baseline of ECG parameters indicating initiation or worsening of axis deviation
Axis deviation is present when QRS axis is greater than +90° or smaller than +30°. Axis deviation will be noted as either present or not present. Any change from baseline will be noted.
Time frame: 6, 12, 24, 36 month
Change from baseline of 6MWD
Time frame: 12, 24, 36 month
Change from baseline of NT-pro BNP levels
Time frame: 12, 24, 36 month
Change from baseline of actigraphy measures as will be measured using an Actigraph Centrepoint Insight Activity monitor
Time frame: 12, 24, 36 month
Change from baseline of Quality of Life (QOL) score using the SF36 questionnaire
PAH patient's WHO functional class is a scale of 1 to 4 based on the symptoms patient experience when doing everyday activities, were Functional Class 1 and 2 are associated with limited effect on patient activity and lower risk status, and Functional Class 3 and 4 are associated with limited activity and higher risk status
Time frame: 12, 24, 36 month
Survival or the cause of mortality
Time frame: 6, 12, 24, 36 month
Amount of Hospitalizations events due to pulmonary arterial hypertension
Time frame: 6, 12, 24, 36 month
Number of patients with clinical worsening of PAH condition resulting with interventional or surgical procedures, such as heart/lung transplant or atrial septostomy.
Time frame: 6, 12, 24, 36 month
Clinical change of pulmonary arterial hypertension condition defined by worsening of patients' WHO functional class
PAH patient's WHO functional class is a scale of 1 to 4 based on the symptoms patient experience when doing everyday activities, were Functional Class 1 and 2 are associated with limited effect on patient activity and lower risk status, and Functional Class 3 and 4 are associated with limited activity and higher risk status
Time frame: 12, 24, 36 month
Clinical change of pulmonary arterial hypertension condition defined by escalation of concomitant drug therapy
Change in the dose of medication
Time frame: 6, 12, 24, 36 month
Clinical change of pulmonary arterial hypertension condition defined by escalation of concomitant drug therapy
Change in the number of concomitant medications
Time frame: 6, 12, 24, 36 month
No study locations are listed for this record.
Start is estimated for Jan 2023; primary completion for Dec 2023, 11 months later.
Of 65 interventional studies with no phase under Pulmonary Arterial Hypertension, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension →
SoniVie Inc.